Life sciences briefing: Thursday, Nov. 1, 2007
Featured companies: Asteres, HemaQuest Pharmaceuticals, Nanosphere, Novalar Pharmaceuticals, Tranzyme Pharma
(UPDATED: Expanded items for Nanosphere, HemaQuest and Transzyme. Moved Novalar to a separate item here.)
Diagnostic maker Nanosphere prices IPO at low end of range, raises up to $113M — Nanosphere, a Northbrook, Ill., biotech focused on nanotech-derived diagnostics, priced its IPO at $14 a share, at the low end of its estimated range. The company, which could sell as many as eight million shares, stands to raise up… Continue Reading
IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings
Bioheart’s IPO-related chest pains continue — The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with patients’ own muscle stem cells. IPO Home now lists the IPO as scheduled on a “day-to-day” basis.
So the jury is still out as to whether the company’s recent halving of its IPO terms will still… Continue Reading
Life sciences briefing: Thursday, Oct. 18, 2007
Featured companies: American Oriental Bioengineering, Guangxi Boke, Inspired Technologies, Nanosphere, Patton Medical Devices
UPDATED: Expanded items on Nanosphere and Patton Medical Devices.
Molecular-diagnostics firm Nanosphere sets IPO range, now expects $129M — Northbrook, Ill.-based Nanosphere, a maker of nanotech-derived molecular diagnostics, now expects to raise up to $129 million by selling as many as eight million shares in an initial offering. The company’s latest SEC filing is here. Nanosphere intends to price its shares between $14 and $16 apiece.
The… Continue Reading
Life sciences briefing: Monday, Aug. 13, 2007
(UPDATED: See below.)
Featured companies: FoldRx Pharmaceuticals, Ophthotech, Pevion Biotech, Restoration Robotics, Glide Pharma, Reliant Pharmaceuticals, Nanosphere, SurModics, BioFX Laboratories
FoldRx Pharma to receive $22M against cystic fibrosis — Cambridge, Mass.-based FoldRx Pharmaceuticals, a biotech focused on diseases that result from misfolded proteins, will get $22 million over the next five years from an affiliate of the Cystic Fibrosis Foundation to further its work against the genetic lung disease. The money will be paid as FoldRx meets various developmental… Continue Reading